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Abstract
Toll-like receptor (TLR)-8 agonists activate adaptive immune responses by inducing robust
production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds may be
promising candidate adjuvants. We recently reported pure TLR8 agonistic activity in a C2-butyl
furo[2,3-c]quinoline. We have obtained the structure of human TLR8 ectodomain co-crystallized
with the furoquinoline compound, which indicates ligand-induced reorganization of the binding
pocket of TLR8. The loss of a key H-bond between the oxygen atom of the furanyl ring of the
agonist and Thr574 in TLR8 suggested that the furan ring was dispensable. We employed a
disconnection strategy and examined 3- and 4-substituted aminoquinolines. Focused structure-
based ligand design studies led to the identification of 3-pentyl-quinoline-2-amine as a novel,
structurally simple, and highly potent human TLR8-specific agonist.
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The immune system protects the host from infectious agents by first recognizing the
presence of the infectious organism and then responding rapidly and appropriately to contain
and eliminate the threat. The mobilization of adaptive immune responses involving T-, and
B-lymphocytic effector functions are exquisitely pathogen-specific, but are relatively slow,
requiring days or weeks.[1] The enormous diversity of infectious organisms and their short
generation times led Janeway to postulate that “the immune system has evolved specifically
to recognize and respond to infectious microorganisms, and that this involves recognition
not only of specific antigenic determinants, but also of certain characteristics or patterns
common on infectious agents but absent from the host.”[2]
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Janeway's seminal ideas of nonclonal recognition of nonself by “Pattern Recognition
Receptors” (PRRs) served as the foundation for the discovery of the sensors of the innate
immune system.[3] Among the well-studied of such PRRs initiating innate immune afferent
signals include the Toll-like receptors (TLRs),[4] of which there are 10 functional TLRs
encoded in the human genome. TLRs -3, -7, -8 and -9 function within the endolysosomal
compartment.[5] The activation of TLRs by their cognate ligands leads to production of
inflammatory cytokines, and up-regulation of major histocompatibility complex molecules
and co-stimulatory signals in antigen-presenting cells as well as activating natural killer cells
(innate immune response).[6] These events lead to the priming of naïve lymphocytes and
subsequent induction and amplification of antigen-specific T-, and B-cell effector functions
(adaptive immune responses).[7]
Our recent efforts on evaluating small molecule agonists of TLR8[8] are primarily aimed at
examining such compounds as potential vaccine adjuvants. TLR8 is expressed in myeloid
dendritic cells, monocytes, and monocyte-derived dendritic cells. Engagement by TLR8
agonists evokes a dominant proinflammatory cytokine profile including tumor necrosis
factor-α (TNF-α, interleukin-12 (IL-12), and IL-18,[9] and appear unique in markedly
upregulating the production of Th1-polarizing cytokines TNF-α and IL-12 in neonatal
antigen presenting cells.[10] These data, taken together, suggest that TLR8 agonists may be
useful as adjuvants for enhancing immune responses in newborns.[11]
A prerequisite for the careful evaluation of TLR8 agonists as potential vaccines adjuvants is
the characterization of pure TLR8 agonists with negligible TLR7 activity, for almost all
known agonists of TLR8 typified by certain imidazoquinolines such as CL097[12] (2, Fig.
1), and thiazoloquinolines such as CL075[13] (1, Fig. 1), and the 2-aminobenzazepine
VTX-2337[14] display mixed TLR7/TLR8-agonism. TLR8-biased agonistic properties have
been described for a novel 2-aminobenzazepine derivative (VTX-294),[15] whose complete
structure has not been disclosed. We recently reported pure TLR8 agonistic activity in a C2-
butyl furo[2,3-c]quinoline 3 (Fig. 1) with IL-12 and IL-18 induction profiles, and yet
without IFN-α inducing properties, confirming its selectivity for human TLR8.[8a] Crystal
structures of the ectodomain of human TLR8 complexed with mixed TLR7/TLR8-agonistic
thiazoloquinolines and imidazoquinolines (including 1 and 2)[16] had allowed a
rationalization of our experimentally-determined SAR via induced-fit docking
techniques.[8a]
The thiazoloquinoline 1 as well as the furoquinoline 3 were predicted to occupy the same
binding pocket formed by both the TLR8 protomers with the binding geometry of the
ligands and interacting residues being virtually identical; ionic H-bonds were observed
between the C4-amine of both 1 and 3 with the sidechain carboxylate of Asp543 of TLR8,
with additional stabilization derived from an H-bond between the β-OH group of Thr574
and either the N2 atom of the thiazole ring of 1 or the oxygen atom of the furanyl ring of 3.
Key ππ interactions of the quinoline moieties of 1 and 3 (Phe405/Tyr353), as well as
hydrophobic interactions of the C2-alkyl group (Phe346/Ile403/Tyr348) were also observed
to occur (Fig. 2).
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Recognizing limitations inherent in docking methods,[17] and cognizant of the
crystallographically determined observation of large structural excursions (15 Å) of the top
lateral face of TLR8 upon ligand binding,[16] we sought to directly verify and validate our
docking results. We were delighted to obtain high-resolution (1.8 Ǻ) structure of human
TLR8 co-crystallized with 3 (Fig. S1, Table S1). An examination of the complex confirmed
similar binding geometries of 2 and 3 (Fig. S2). The occupancy of TLR8 with 3 induced, as
expected, a significant reorganization to form the binding pocket, reflected in significant Cα
deviations (Fig. 3A) corresponding primarily to loops of leucine-rich repeats (LRRs) (Fig.
3B). However, the occupancy of 3 in TLR8 is associated with greater excursions of LRR8
and, particularly, of residues 572-574 in LRR18 such that predicted H-bond between Thr574
and the oxygen atom of the furanyl ring of 3 is lost in the crystal structure of the complex
(Fig. 3C). This led us to hypothesize that the furan ring in 3 was dispensable, and we
envisaged simpler 3- and 4-substituted aminoquinolines via classic disconnection
strategies[18] as shown schematically in Fig. 4. We first targeted the 3-alkoxy-2-
aminoquinoline series derived by disconnection at C1 in 3. The 3-butoxy analogue 6 was
synthesized from commercially-available 3-hydroxy quinoline via O-alkylation and
installation of the amine at C2 using reported methods (Scheme 1).[8a, 13b, 19] A homologous
series of compounds were also synthesized (Scheme S1). As in other chemotypes that we
had previously explored,[8a, 13b, 19b, 20] and consistent with the dimensions of the binding
pocket in TLR8,[16] we observed in this homologous series a clear dependence of substituent
chain length at C3 with the optimal analogue being 6, which showed maximal agonistic
potency in a cell-based TLR8-specific NF-κB transactivation assay (EC50 of 2.2 μM; Figs.
5, S3, Table 1). We reasoned that the electronegativity of the heteroatom at C3 may
differentially modulate electron density of the quinoline ring and thus affect both the
strength of the salt-bridge of the C2-amine with Asp543, as well as ππ interactions with
Phe405. We therefore synthesized N3- butylquinoline and 3-(butylthio)quinoline analogues
(9 and 12, respectively), as well as the 3-alkylquinolin-2-amines 14a-f (Scheme 1).
Accessing the N3-butylquinoline 9 by conventional strategies via N-oxidation of the
commercially available 3-aminoquinoline was problematic, and we found it expedient to
utilize as starting material 2-chloro-3-azidoquinoline 7 (derived from commercially
available 2-chloro-3-quinolineboronic acid, see Supporting Information). S-alkylation of 3-
bromoquinoline 1-oxide obviated the problem of over-oxidation to the sulfone derivative
(which was found to be completely inactive) in the synthesis of the 3-(butylthio)quinoline
12.
A comparison of the activities of these analogues in TLR8 primary screens yielded a clear
structure-activity relationship. The TLR8-agonistic potency of the 3-pentyl quinoline 14b
was 0.2 μM, i.e., ten-fold greater than that of the 3-butoxy analogue 6b, eight times greater
than that of the parent compound 3 (EC50: 1.6 μM), and rivaling that of the reference
compound 1 (Fig. 5, Table 1), while the 3-(butylthio)quinoline and N3- butylquinoline
analogues were weaker (EC50: 4.2 μM and 4.3 μM for 12 and 9, respectively; Fig. 5, Table
1).
An examination of the dihedral angles indicated a quasi-gauche conformation of the
proximal methylenes of the C2-butyl substituent in the crystal structure of 3 bound to TLR8
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and, as expected, the introduction of unfavorable geometrical constraints in the (E)-3-
(pent-1-en-1-yl)quinoline and 3-(pent-1-yn-1-yl)quinoline analogues 14d and 14f,
respectively, diminishes activity while potency is largely spared in compound 14e with a
terminal alkene (Fig. 5, Table 1).
Additionally, in examining the interfacial surface topology of the binding site formed by the
protomers of TLR8[16] using Voronoi polyhedral modeling,[21] we noticed an accessory
hydrophobic groove bounded by Phe346 and Tyr348 which is contiguous with the
hydrophobic pocket accommodating the C2-butyl substituent in 3. We were therefore
interested in examining whether additional substituents at C4 would further augment the
potency of 14b. As shown in Scheme 2, analogues 21a-c were synthesized starting from 3-
iodoquinolin-4-ol (15).[8a]
We had initially envisaged a step-wise Suzuki coupling of appropriate alkylboronic acids
with the 3-iodo-4-chloroquinoline intermediate 16 which, however, was not optimal because
of the formation of a mixture of isomers. We therefore first installed the 3-pentyne
substituent by Sonogashira coupling to obtain 17, which proved to be an excellent substrate
for subsequent Suzuki coupling, leading to the required analogues 21a-c (Scheme 2). These
compounds were feeble in their TLR8-agonistic activity (data not shown), suggesting poor
tolerance of steric bulk at C4. In order to confirm that substitutions at C4 are not tolerated,
we synthesized congeners of both 4-alkoxy (24a-b) and 4-alkyl quinolin-2-amines (27a-b;
Scheme 3) and, as expected, all of these analogues were found to be inactive (Table S2).
All analogues were counter-screened[8c, 19b, 22] in reporter cell lines specific for human
TLR2, TLR3, TLR4, TLR5, TLR7, TLR9, TLR10, Nod1 and Nod2, and compounds 6, 9,
12, and 14a-f were confirmed to be specific for human TLR8. The most potent analogue 14b
was characterized further in cytokine/chemokine induction profiles in a panel of secondary
screens employing human peripheral blood mononuclear cells[8a] as well as whole human
blood.[22c] Consistent with its specificity for TLR8, we observed the induction of a specific
set of chemokines and proinflammatory cytokines, including interleukins 12 and 18 (Fig. 6).
In summary, we have effectively utilized the structure of TLR8 complexed with ligands in
the rational design of a novel TLR8-specific chemotype which retains prominent cytokine-
inducing activity profiles in ex vivo human blood assay systems, paving the way for
evaluation of this compound as a candidate vaccine adjuvant in appropriate animal models.
Experimental Section
X-ray diffraction data and all synthetic and immunological experimental methods are
provided in the Supporting Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Representative heterocyclic small molecules with TLR8 agonistic activity.
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Induced-fit docking[8a] of 3 in human TLR8 (PDB ID: 3W3K) showing an salt bridge
between the C4-amine and D543*, and an H-bond between the furanyl oxygen atom and
T574. Interacting residues in protomers A and B (*) are highlighted in green and cyan,
respectively.
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A. Cα deviation in TLR8 bound to 3 versus unliganded TLR8. B. Regions undergoing
ligand-induced Cα movements of more than 2.5 Ǻ are shown in red for the TLR8
protomers. C. TLR8 (protomers A and B represented in green and cyan, respectively)
complexed with 3 showing the loss of H-bond of the furanyl oxygen atom due to
reorganization of residues in the binding pocket (PDB code: 3WN4).
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Disconnection strategy of 3 leading to substituted aminoquinolines.
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Syntheses of 3-substituted quinolin-2-amine analogues. Reagents: (i) butyl iodide, K2CO3,
DMSO; (ii) m-CPBA, CHCl3; (iii) (a) benzoyl isocyanate, CH2Cl2; (b) NaOMe, MeOH; (iv)
H2, Pt/C, EtOH; (v) NH3, MeOH; (vi) butylSH, NaH, DMSO; (vii) Pd(PPh3)4, RB(OH)2,
K2CO3, 1,4-dioxane, for 14f: Pd(PPh3)4, CuI, 1-pentyne, Et3N:CH3CN (1:3).
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Dose-response profiles of human TLR8 agonistic activities of 3-substituted 2-
aminoquinolines. Error bars represent standard deviations obtained on quadruplicates.
Compounds 1 and 3 were used as comparators.
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4-alkyl-3-pentylquinolin-2-amines. Reagents: (i) POCl3; (ii) Pd(PPh3)4, CuI, 1-pentyne,
Et3N:CH3CN (1:3); (iii) Pd(PPh3)4, RB(OH)2, K2CO3, 1,4-dioxane (iv) H2, Pt/C, EtOH; (v)
m-CPBA, CHCl3; (vi) (a) benzoyl isocyanate, CH2Cl2; (b) NaOMe, MeOH.
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4-substituted quinolin-2-amines. Reagents: (i) butyl iodide, NaH, DMSO; (ii) m-CPBA,
CHCl3; (iii) (a) benzoyl isocyanate, CH2Cl2; (b) NaOMe, MeOH; (iv) POCl3; (v)
Pd(PPh3)4, RB(OH)2, K2CO3, 1,4-dioxane.
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Induction of cytokines (red) and chemokines (blue) in human PBMCs by the lead compound
14b. Means of triplicates are shown.
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Table 1
EC50 values of human TLR8-specific agonistic activities.













1 (Ref. 1) 2-propylthiazolo[4,5-c]quinolin-4-amine 0.2
3 (Ref. 2) 2-butylfuro[2,3-c]quinolin-4-amine 1.6
a
EC50 values were obtained using hTLR8-specific reporter gene assays.
b
Inactive compounds did not show appreciable activity at 500 μM.
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